biostudies-literatureGeorge RENCRR NIH HHSNCI NIH HHSNINDS NIH HHS629-38https://www.ebi.ac.uk/biostudies/studies/S-EPMC3025700biostudies-literatureUnknown55(4)<h4>Background</h4>Demethylating agents may alter the expression of genes involved in chemotherapy resistance. We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors.<h4>Procedure</h4>Stratum A included children with any solid tumor; Stratum B included neuroblastoma patients only. Patients received a 1-hr decitabine infusion for 7 days, followed by doxorubicin (45 mg/m(2)) and cyclophosphamide (1 g/m(2)) on day 7. Pharmacokinetic studies were performed after the first dose of decitabine. Biological studies included methylation and gene expression analyses of caspase-8, MAGE-1 and fetal hemoglobin (HbF), and expression profiling of pre- and postPediatric blood & cancerPhase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.PMC3025700K08NS047983U01 CA97452K08 NS047983U01 CA097452M01 RR00188R01 CA067938M01 RR000188Krailo MGeorge REFinkelstein DNeuberg DBlaney SMDiller LAdamson PCZhu KIngle AMLahti JMReid JMfalsePhase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study.<h4>Background</h4>Demethylating agents may alter the expression of genes involved in chemotherapy resistance. We conducted a phase I trial to determine the toxicity and molecular effects of the demethylating agent, decitabine, followed by doxorubicin and cyclophosphamide in children with refractory solid tumors.<h4>Procedure</h4>Stratum A included children with any solid tumor; Stratum B included neuroblastoma patients only. Patients received a 1-hr decitabine infusion for 7 days, followed by doxorubicin (45 mg/m(2)) and cyclophosphamide (1 g/m(2)) on day 7. Pharmacokinetic studies were performed after the first dose of decitabine. Biological studies included methylation and gene expression analyses of caspase-8, MAGE-1 and fetal hemoglobin (HbF), and expression profiling of pre- and post2010-01-01T00:00:00Z2010 Oct2025-04-04T00:28:57.315Z2019-03-27T00:38:22ZS-EPMC30257002058965110.1002/pbc.22607